Executive interview – TiGenix

Executive interview – TiGenix

TiGenix is set for a decisive 2017 with possible EMA approval in H2 of the allogeneic stem cell therapy Cx601 to treat complex perianal fistulas in Crohn’s disease. This will trigger a €15m milestone from Takeda, the European partner; Takeda views Cx601 as a breakthrough therapy. A Phase I/II trial using stem cells to control severe sepsis, a major unmet need, has just started. Another interesting project is on acute cardiac stem cell therapy; Phase I/II data are expected in H117. The US IPO raised €31m net in 2016.


You may also be interested in these:

Investment Companies

IP Group - executive interview

Investment Companies

Oakley Capital Investments – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free